Page 2 - Ajay Nirula News Today

Eli Lilly is entering the field of protein-degrading drugs through a partnership with Lycia Therapeutics, a startup whose technology goes further than the first wave of such drugs. Lilly paid $35 million to begin the alliance, which spans up to five drugs.

Lilly, Rigel Launch Up-to-$960M Partnership to Develop RIPK1 Inhibitors February 19, 2021 Eli Lilly will partner with Rigel Pharmaceuticals to co-develop and commercialize Rigels Phase II-bound R552 for all indications—which they emphasized would include autoimmune and inflammatory diseases—through a collaboration that could generate close to $1 billion for the South San Francisco, CA, biotech. [Eli Lilly] Share Eli Lilly will partner with Rigel Pharmaceuticals to co-develop and commerciali...

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 /PRNewswire/ -- Eli Lilly and Company and Rigel Pharmaceuticals, Inc. today announced a global exclusive license agreement and... | February 22, 2021

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive license agreement and...

UC San Francisco scientists have formed a research alliance with pharmaceutical firm Eli Lilly and Company aimed at better understanding autoimmune diseases and fostering the development of new therapies. Based on the innovative Immunoprofiler model launched at UCSF in 2017, the new initiative, called AutoImmunoprofiler, inherits the most successful aspects of its predecessor and adapts them to the study of autoimmunity.  Autoimmune diseases such as lupus, inflammatory bowel disease, and typ...

By Ian McConnell

Search jobs UofG Announces Research Collaboration with Lilly to Discover Potential New Drug Targets The University of Glasgow has entered into a research collaboration with pharmaceutical company Eli Lilly and Company, that aims to discover and validate the next generation of drug targets for immunological diseases. The £4.6million research collaboration, due to last four years, will work across four diseases – psoriatic arthritis, rheumatoid arthritis, fibrosis and ...